Skip to main content
. 2020 Aug 21;12(9):2370. doi: 10.3390/cancers12092370

Figure 6.

Figure 6

CAPE-MotAb possesses enhanced anti-migration and anti-invasion activity. (A) Wound scratch assay showing that CAPE-MotAb treated A549 cells moved slower when compared to the other two groups as indicated in the open area of the wound (CAPE concentration: 5 μg/mL). Quantitation of the open area from three independent experiments (mean ± SD, n = 3), * p < 0.05, ** p < 0.01, *** p < 0.001 (Student’s t-test to control). (B) Representative images of the invasion assay exhibiting impaired invasion in CAPE-MotAb treated A549 cells. Quantitation of cell invasion results from three independent experiments (mean ± SD, n = 3), *** p < 0.001 (Student’s t-test). A549 cells were treated with an equivalent dose of CAPE (10 µg/mL) for 24 h. (C) Western blot analysis for metastasis-associated proteins (MMP2, MMP3, MMP9, hnRNP-k, CARF, and Vimentin) after 48 h incubation of cells with CAPE-MotAb (10 µg/mL). Quantitation of the results is shown on the right (mean ± SD, n = 3), * p < 0.05, ** p < 0.01, *** p < 0.001 (Student’s t-test to control).